



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

September 30, 2019

National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex
Bandra (E)
Mumbai 400 051

Scrip Code : JBCHEPHARM

Dear Sir,

Sub: News about presence of NDMA in Ranitidine

We refer to the recent news about presence of impurity, N-nitrosodimethylamine (NDMA) in active pharmaceutical ingredient (API) Ranitidine.

We are manufacturers of RantacTM formulations where Ranitidine API is manufactured by third party vendors.

Following this news, our API vendors have got their product analyzed as per international guidelines to verify the presence of NDMA. They have reported that the NDMA is well within the permissible limits.

In addition, the Company has also initiated analysis of the samples of all Rantac formulations for the presence of NDMA. We have to inform that initial report received indicate NDMA is well within the permissible limit.

As a responsible supplier of Rantac, we always take and shall continue to take all steps necessary for patient's safety including those directed by the Drugs Controller General (India). We wish to add that Rantac is being marketed by the Company for over 3 decades and so far no serious adverse events have been reported. We continue to manufacture and sell the product as per the approved regulatory specifications.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta

Company Secretary & Vice President - Compliance

📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
📠 +91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380